Carvolix: Strategic Transformation and 2025 Financial Results

Carvolix, formerly Affluent Medical, has published its financial results for 2025. The company has undergone a strategic shift towards interventional cardiology with the acquisition of Caranx Medical and Artedrone. These acquisitions aim to strengthen its position in medical robotics and cardiovascular implants. Initial funding of €10 million has been secured from Truffle Capital and Edwards Lifesciences.

Carvolix has launched TAVIPILOT software in the United States, designed for AI-guided heart valve implantation. Clinical results are promising, with a study in Australia demonstrating a 100% success rate. The company is also continuing the development of other products, such as the Kalios mitral valve ring and the Artus urinary sphincter.

The financial results estimate a net loss of 24.971 million euros, but the strategy is to capitalize on the market potential, estimated at 23 billion euros.